Perspective Therapeutics (CATX) highlights Phase 1/2a [212Pb]VMT-α-NET data in NETs at ASCO GI 2026

Rhea-AI Filing Summary

Perspective Therapeutics, Inc. reported that it issued a press release on January 9, 2026 sharing updated interim data from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET. This study involves patients with unresectable or metastatic neuroendocrine tumors that express somatostatin receptor subtype 2, a specific tumor marker. The updated data are being presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, held January 8–10, 2026 in San Francisco. Detailed clinical results are contained in the related press release, which is attached as an exhibit.

Insights

Biotech clinical development analyst

Perspective highlights early-stage trial data for [212Pb]VMT-α-NET in neuroendocrine tumors at a major cancer meeting.

Perspective Therapeutics is drawing attention to updated interim results from a Phase 1/2a trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor subtype 2-expressing neuroendocrine tumors. Presenting data at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium signals that the program is progressing through early clinical evaluation.

The information provided focuses on the fact of the update and its presentation venue rather than specific efficacy or safety results. As a Phase 1/2a study, the main goals typically include assessing safety, dosing, and early signals of activity, but this excerpt does not describe the findings. The detailed implications for the program depend on the data contained in the referenced press release.

The timing aligns with the January 8–10, 2026 ASCO Gastrointestinal Cancers Symposium in San Francisco, which can increase scientific and clinical visibility for the asset. Subsequent disclosures in company communications may further clarify how these interim data inform future trial design and development steps for [212Pb]VMT-α-NET in neuroendocrine tumors.

0000728387false00007283872026-01-092026-01-09

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 09, 2026

Perspective Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-33407	41-1458152
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
c/o Perspective Therapeutics, Inc. 2401 Elliott Avenue Suite 320
Seattle, Washington				98121
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 676-0900

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		CATX		NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On January 9, 2026, Perspective Therapeutics, Inc. issued a press release announcing certain updated interim data from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor subtype 2-expressing neuroendocrine tumors (NETs) that are being presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium taking place from January 8-10, 2026 in San Francisco, California. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release dated January 9, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			PERSPECTIVE THERAPEUTICS, INC.
Date:	January 9, 2026	By:	/s/ Johan (Thijs) Spoor
			Johan (Thijs) Spoor Chief Executive Officer

FAQ

What did Perspective Therapeutics (CATX) announce in this 8-K?

Perspective Therapeutics reported that on January 9, 2026 it issued a press release with updated interim data from its Phase 1/2a trial of [212Pb]VMT-α-NET in neuroendocrine tumors. The press release is included as Exhibit 99.1.

Which clinical trial is highlighted by Perspective Therapeutics (CATX)?

The company highlighted a Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor subtype 2-expressing neuroendocrine tumors.

For which patients is [212Pb]VMT-α-NET being studied by CATX?

[212Pb]VMT-α-NET is being evaluated in patients with unresectable or metastatic neuroendocrine tumors that express somatostatin receptor subtype 2.

Where and when are Perspective Therapeutics’ updated trial data being presented?

The updated interim data are being presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, which takes place from January 8–10, 2026 in San Francisco, California.

Where can investors find the detailed clinical data mentioned by Perspective Therapeutics (CATX)?

The detailed information is contained in the company’s press release dated January 9, 2026, which is filed as Exhibit 99.1 to this report and incorporated by reference.

What exhibits did Perspective Therapeutics include with this report?

The report includes Exhibit 99.1, a press release dated January 9, 2026, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.